Krystal Biotech announced that the U.S. Centers for Medicare & Medicaid Services, CMS, has assigned a permanent and product-specific J-code for VYJUVEK, the first U.S. Food and Drug Administration-approved treatment for dystrophic epidermolysis bullosa, DEB. The J-code for VYJUVEK became effective on January 1, 2024. “The permanent J-code will help ensure efficient and accurate reimbursement of VYJUVEK and further enable us to bring this important treatment to DEB patients in need,” said Krish Krishnan, Chairman & CEO at Krystal Biotech
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KRYS:
- Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®
- Krystal Biotech receives ODD from Japanese MHLW for B-VEC
- Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)
- 3 Best Stocks to Buy Now, 12/14/2023, According to Top Analysts
- William Blair says buy these stocks for 2024